LeMaitre Vascular Toekomstige groei
Future criteriumcontroles 1/6
De verwachting is dat LeMaitre Vascular de winst en omzet met respectievelijk 9.5% en 8.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 8.3% per jaar.
Belangrijke informatie
9.5%
Groei van de winst
8.29%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 16.4% |
| Inkomstengroei | 8.8% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 25 Jun 2026 |
Recente toekomstige groei-updates
Analyseartikel • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analyseartikel • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Recent updates
Analyseartikel • Jun 20
LeMaitre Vascular (LMAT) Stock Could Be 20.9% Undervalued on Its International Growth Narrative
LeMaitre Vascular (LMAT) is back in focus after recent share price moves, with the stock last closing at US$93.95. Investors are weighing this level against the company’s fundamentals and recent return profile. See our latest analysis for LeMaitre Vascular. Recent momentum in LeMaitre Vascular has been mixed, with a 1-day share price return of 1.89% and a year to date share price return of 17.19%, while the 1-year total shareholder return stands at 15.94% and the 5-year total shareholder...
Narratiefupdate • Jun 11
LMAT: Future Cash Returns May Support Raised 2026 Guidance And Premium P/E
Analysts have lifted their price target on LeMaitre Vascular by $25, citing updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E as key drivers of their revised view. Analyst Commentary Recent research updates on LeMaitre Vascular show a cluster of price target increases and a neutral initiation, providing a mix of both optimistic and cautious viewpoints on the stock.Narratiefupdate • May 28
LMAT: Future Cash Returns May Support Raised Earnings Guidance And Premium P/E
LeMaitre Vascular's analyst price target has been updated to $118.75 from $111.22, as analysts factor in revised fair value assumptions, a slightly lower discount rate, modestly adjusted revenue growth expectations, and a higher projected P/E multiple supported by recent research updates from multiple firms. Analyst Commentary Recent research updates show a cluster of higher price targets for LeMaitre Vascular, alongside at least one more neutral stance, giving you a mix of optimistic and cautious views to weigh.Narratiefupdate • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Narratiefupdate • Apr 13
LMAT: Future Margin Discipline And Cash Returns May Support Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular now reflects a modestly higher fair value estimate of about $111.22. This is supported by Street research that highlights continued double digit organic sales growth, material margin expansion, strong cash flow and operating leverage in the wake of better than expected Q4 results and guidance.Narratiefupdate • Mar 29
LMAT: Future Cash Returns And Margin Discipline May Sustain Current Premium
Narrative Update Analysts have raised LeMaitre Vascular's price targets by $10 to $12, now in a $105 to $117 range. They cite double digit organic revenue growth, margin expansion, strong cash flow, better than expected Q4 results, and operating leverage.Narratiefupdate • Mar 14
LMAT: Future Margin Execution And Capital Returns May Support Current Premium
Narrative Update on LeMaitre Vascular Our analyst fair value estimate for LeMaitre Vascular has been lifted from $109.22 to $111.00, reflecting updated price targets from $95 to $105 and from $108 to $117 as analysts point to double digit organic growth, margin expansion, and operating leverage following better than expected Q4 results and guidance. Analyst Commentary Recent price target increases to $105 and $117 signal that bullish analysts are incorporating stronger fundamentals into their models following the latest Q4 print and guidance.Narratiefupdate • Feb 28
LMAT: Future Margin Gains And Capital Returns May Sustain Current Premium
Analysts have increased their implied fair value estimate for LeMaitre Vascular by about $4 to roughly $109, citing recent price target increases to $105 and $117 that they attribute to double-digit organic sales growth, margin expansion and operating leverage. Analyst Commentary Bullish Takeaways Bullish analysts point to double digit organic sales growth as a key support for their higher fair value views, seeing current revenue trends as consistent with a premium valuation versus slower growing peers.Seeking Alpha • Feb 27
LeMaitre Vascular: The Compounder Keeps Compounding
Summary LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft’s international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program. Operating leverage, pricing power, and international expansion are all key drivers in raising my price target to $116-$130 for year-end 2026. I reiterate my Buy rating. Read the full article on Seeking AlphaAnalyseartikel • Feb 06
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Jan 03
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
With a price-to-earnings (or "P/E") ratio of 34.1x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analyseartikel • Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Analyseartikel • Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Key Insights LeMaitre Vascular's estimated fair value is US$68.59 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) price-to-earnings (or "P/E") ratio of 40.5x might make it look like a strong...Analyseartikel • Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analyseartikel • Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) dividend will be increasing from last year's payment of the same period to...Analyseartikel • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analyseartikel • Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it received a lot of...Analyseartikel • Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Jan 15
LeMaitre Vascular: Losing Steam
Summary LeMaitre Vascular, Inc. has seen a 65% stock rise over 12 months but trades at high valuations with decelerating growth projections. Q3 results showed strong performance with 46% profit growth and 15.7% revenue increase, driven by grafts, patches, and carotid shunts. The stock has dipped some 15% recently. Buy the dip? An analysis around LeMaitre Vascular follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights LeMaitre Vascular's estimated fair value is US$96.24 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analyseartikel • Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Nov 03
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Summary LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. Read the full article on Seeking AlphaAnalyseartikel • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Analyseartikel • Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it saw a double-digit...Analyseartikel • Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Nieuw narratief • Sep 11
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.Analyseartikel • Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 23
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Summary I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected. Read the full article on Seeking AlphaAnalyseartikel • Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Key Insights LeMaitre Vascular's estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Analyseartikel • Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analyseartikel • May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 49.8x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analyseartikel • Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights The projected fair value for LeMaitre Vascular is US$68.32 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 333 | 83 | 92 | 118 | 4 |
| 12/31/2027 | 306 | 76 | 86 | 94 | 9 |
| 12/31/2026 | 280 | 69 | 70 | 80 | 9 |
| 3/31/2026 | 256 | 62 | 79 | 87 | N/A |
| 12/31/2025 | 250 | 58 | 74 | 81 | N/A |
| 9/30/2025 | 241 | 53 | 66 | 73 | N/A |
| 6/30/2025 | 235 | 47 | 52 | 59 | N/A |
| 3/31/2025 | 226 | 45 | 41 | 48 | N/A |
| 12/31/2024 | 220 | 44 | 37 | 44 | N/A |
| 9/30/2024 | 213 | 41 | 33 | 40 | N/A |
| 6/30/2024 | 206 | 38 | 32 | 37 | N/A |
| 3/31/2024 | 200 | 34 | 33 | 40 | N/A |
| 12/31/2023 | 193 | 30 | 29 | 37 | N/A |
| 9/30/2023 | 186 | 27 | 23 | 30 | N/A |
| 6/30/2023 | 177 | 25 | 19 | 26 | N/A |
| 3/31/2023 | 169 | 21 | 18 | 23 | N/A |
| 12/31/2022 | 162 | 21 | 22 | 25 | N/A |
| 9/30/2022 | 160 | 21 | 24 | 26 | N/A |
| 6/30/2022 | 160 | 22 | 29 | 33 | N/A |
| 3/31/2022 | 158 | 27 | 29 | 34 | N/A |
| 12/31/2021 | 154 | 27 | 30 | 35 | N/A |
| 9/30/2021 | 152 | 28 | 39 | 44 | N/A |
| 6/30/2021 | 151 | 29 | 40 | 44 | N/A |
| 3/31/2021 | 135 | 24 | 37 | 40 | N/A |
| 12/31/2020 | 129 | 21 | 32 | 35 | N/A |
| 9/30/2020 | 122 | 19 | 23 | 26 | N/A |
| 6/30/2020 | 115 | 16 | 13 | 17 | N/A |
| 3/31/2020 | 119 | 18 | 12 | 16 | N/A |
| 12/31/2019 | 117 | 18 | N/A | 14 | N/A |
| 9/30/2019 | 115 | 19 | N/A | 15 | N/A |
| 6/30/2019 | 111 | 18 | N/A | 15 | N/A |
| 3/31/2019 | 108 | 23 | N/A | 16 | N/A |
| 12/31/2018 | 106 | 23 | N/A | 20 | N/A |
| 9/30/2018 | 103 | 21 | N/A | 20 | N/A |
| 6/30/2018 | 104 | 22 | N/A | 24 | N/A |
| 3/31/2018 | 103 | 18 | N/A | 24 | N/A |
| 12/31/2017 | 101 | 17 | N/A | 23 | N/A |
| 9/30/2017 | 98 | 15 | N/A | 20 | N/A |
| 6/30/2017 | 96 | 14 | N/A | 18 | N/A |
| 3/31/2017 | 93 | 12 | N/A | 18 | N/A |
| 12/31/2016 | 89 | 11 | N/A | 17 | N/A |
| 9/30/2016 | 86 | 11 | N/A | 17 | N/A |
| 6/30/2016 | 82 | 9 | N/A | 14 | N/A |
| 3/31/2016 | 79 | 9 | N/A | 13 | N/A |
| 12/31/2015 | 78 | 8 | N/A | 11 | N/A |
| 9/30/2015 | 76 | 7 | N/A | 10 | N/A |
| 6/30/2015 | 74 | 6 | N/A | 9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei LMAT ( 9.5% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van LMAT ( 9.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 18.5% per jaar).
Hoge groeiwinsten: De winst van LMAT zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van LMAT ( 8.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 12.6% per jaar).
Hoge groei-inkomsten: De omzet van LMAT ( 8.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van LMAT naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/28 05:15 |
| Aandelenkoers aan het einde van de dag | 2026/06/26 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
LeMaitre Vascular, Inc. wordt gevolgd door 19 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |